What FDA’s record states
| Field | What FDA’s record states | Source |
|---|---|---|
| Recipient | RonanRx, Inc. dba RonanRx | FDA letter ↗ |
| Location | Not published by FDA | n/a |
| Letter date | Oct 30, 2026 | FDA letter ↗ |
| Posted by FDA | Nov 3, 2026 | FDA index ↗ |
| Issuing office | Center for Drug Evaluation and Research (CDER) | FDA letter ↗ |
| Subject | False & Misleading Claims/Misbranded (Telehealth) | FDA letter ↗ |
| MARCS-CMS number | 737905 | FDA letter ↗ |
| GLP-1 drugs named | Semaglutide, Tirzepatide | FDA letter ↗ |
| Response letter | Not published by FDA | FDA letter ↗ |
| Closeout letter | Not published by FDA | FDA letter ↗ |
“FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products.”FDA warning letter to RonanRx, Inc. dba RonanRx, Oct 30, 2026 · read the full letter on fda.gov ↗
What this is and is not. A warning letter is FDA’s statement of what it considers significant violations. It is an allegation, not a court finding, and the firm can respond. A closeout letter is posted when FDA confirms the violations were corrected.
Source
Every field above is copied from FDA’s page for this letter, read Nov 18, 2026. The letter on fda.gov ↗ · All 164 GLP-1 warning letters



